This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
A team of scientists at the National Institutes of Health has developed an eye d...
Cardio-focused company Kardigan is sewing a new digital data platform into its R...
As it faces uncertainty in the research market at home and abroad, Illumina is m...
The drug discovery pact between Charles River Laboratories, Valo Health and Flag...
Acrivon Therapeutics is halting work on developing its lead drug for ovarian and...
ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to ...
As it gears up to submit an approval application next year, Wave Life Sciences h...
Responding to the progress of its obesity pipeline, the Chinese biotech is stepp...
The Senate has confirmed President Donald Trump’s pick Jayanta Bhattacharya, M.D...
The series E round follows the launch of Supira's U.S. feasibility study, which ...
Newronika's AlphaDBS system continuously adjusts its output based on real-time b...
Nkarta is laying off a third of its employees, including half of the biotech’s e...
Cell- and gene-therapy-focused ElevateBio has let go of 17% of staffers as part ...
Equillium’s phase 3 graft-versus-host disease trial has missed its primary endpo...
Eye care giant Alcon appears to have gained the upper hand in the ongoing power ...
The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH wo...
Candel Therapeutics has identified a subpopulation of lung cancer patients livin...
Arbutus Biopharma is stripping its workforce back to just a “core team” needed t...
Tara Schwetz, Ph.D., a deputy director at the National Institutes of Health and ...
Lyndra Therapeutics, which spun out of Moderna co-founder Robert Langer’s lab at...
According to the FDA’s public database, since the start of this year the agency ...
Abbott is joining the worldwide race to make pulsed field ablation the standard ...
Before Jazz Pharmaceuticals inked a $935 million deal for Chimerix, the biotech ...
Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressin...